How Hospitals Plan To Put Pressure On Generic-Drug Makers [Investor's Business Daily]
Aclaris Therapeutics, Inc. (ACRS)
Last aclaris therapeutics, inc. earnings: 2/25 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
aclaristx.com
Company Research
Source: Investors Business Daily
Technology Related news 1/16/2018 Alder could successfully compete with larger rivals Amgen, Lilly and Teva in preventing chronic migraines, analysts said Tuesday. Mylan Hits 80-Plus Relative Strength Rating Benchmark Miles White's Bold Moves Made Abbott Laboratories A Global Force Stocks Showing Improved Relative Strength: Lannett Mylan Sees RS Rating Improve To 75 Stocks Generating Improved Relative Strength: Lannett This Group Leader's Breakout Speaks Volumes Teva Pharma Dips After Reaffirming Plan To Cut Jobs In Israel Amid Strike Big Pharma Feels Sting From Increase In Generic Drug Availability Teva Pharmaceutical ( TEVA ) and Mylan ( MYL ) were among a group of generic drugmakers hit Thursday after a consortium of hospitals said they would make medicines themselves to circumvent rising drug prices. X An estimated 300 hospital groups are involved in the effort, which would create a nonprofit company to provide generic medicine
Show less
Read more
Impact Snapshot
Event Time:
ACRS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACRS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACRS alerts
High impacting Aclaris Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ACRS
News
- Cryopyrin-Associated Periodic Syndrome Drug Pipeline Report 2024: Therapeutic Developments for Zydus Cadila, Novartis, Inflazome, Roche, Aclaris Therapeutics, and Mabpharm [Yahoo! Finance]Yahoo! Finance
- Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive Officer [Yahoo! Finance]Yahoo! Finance
- Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive OfficerPR Newswire
- Favourable Signals For Aclaris Therapeutics: Numerous Insiders Acquired Stock [Yahoo! Finance]Yahoo! Finance
- Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year? [Yahoo! Finance]Yahoo! Finance
ACRS
Earnings
- 2/27/24 - Beat
ACRS
Sec Filings
- 4/25/24 - Form ARS
- 4/25/24 - Form DEFA14A
- 4/25/24 - Form DEF
- ACRS's page on the SEC website